BNTX: BioNTech Inc. Price to Sales
BioNTech SE (BNTX) attracts leading immunologists through large-scale scientific investments and ambitious goals. The price-to-sales ratio confirms this strategy, where the value 7.50 reflects the current metric. Leadership is driven by a flexible mRNA platform for combating cancer and viruses, while supply reliability is guaranteed by streamlined cold-chain logistics.
Metric breakdowns and analytics for BioNTech Group (BNTX)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
BNTX - Net Profit|Expected Net Income BioNTech SE|BNTX - Price to Earnings Ratio|Future Price to Earnings Multiple BioNTech Inc.|BNTX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Group|BNTX - Operating profit EBITDA|Net earnings per one share for the last twelve months BioNTech|BNTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biontech.de|BNTX - Earnings per share growth in current year|Projected earnings per share growth rate for next year BioNTech SE
- issuer revenue and sales details:
Summary company analytics:biontech.de
The lack of a commercial drug portfolio and a dependence on costly R&D projects deprive BioNTech SE (BNTX) of the ability to influence market pricing. This capitalization-to-revenue ratio measures the premium over current sales, allowing investors to assess the risk of overpaying for future expectations; meanwhile, inflated metric values signal a potential correction in the asset's value in the absence of new growth drivers.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple ABVX (Abivax S.A.)|ADMA Biologics Inc (ADMA) - Price to Sales|Protagonist Therapeutics Inc - P/S Multiple|IMVT: Price-to-Revenue Ratio|KNSA: P/S Multiple|GRFS - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Adaptive Biotechnologies Corporation|Price to Sales Celldex Therapeutics Inc CLDX|Price-to-Revenue Ratio Aurinia Pharma (AUPH)|BioCryst Corp - Market Cap to Revenue Ratio|Vera Therapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume DNTH (dianthustx.com)|Pharvaris - P/S Multiple|Price to Sales AbCellera Biologics Inc.|TRML: P/S Multiple|Market Cap to Revenue Precigen Corp|PHAR (Pharming Group N.V.) - P/S Multiple|NKTR: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue UPB (Upstream Bio)|ZBIO (Zenas Bio) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Immunome Corp IMNM|Price-to-Revenue Coefficient Gossamer Bio Corp. (GOSS)|KalVista Pharmaceuticals - P/S Multiple|Price to Sales septerna.com|PVLA: P/S Multiple|SVRA (Savara Inc) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Rigel Pharmaceuticals Inc|Market Cap to Revenue Ratio ANAB (AnaptysBio Inc.)|Market Cap to Revenue ATXS (Astria Therapeutics)|Market Cap to Sales Volume ENGN|RAPT Therapeutics - Market Cap to Revenue|JBIO: Market Cap to Revenue Ratio|ACRS - Price-to-Revenue Ratio|Price-to-Sales Ratio KYTX|TLSA: P/S Multiple|cabalettabio.com - Market Capitalization-to-Revenue Ratio|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|P/S Multiple Theratechnologies, Inc.|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|ELDN (Eledon Pharmaceuticals, Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Agenus AGEN|CLYM - Market Cap to Revenue|Zura Bio - P/S Multiple|ATYR - P/S Multiple|ADAG (adagene.com) - Market Cap to Revenue|Ikena Oncology - Market Capitalization-to-Revenue Ratio|STTK (Shattuck Labs Inc) - P/S Multiple|Equillium Bio (EQ) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Market Cap to Revenue immunic-therapeutics.com IMUX|Price-to-Revenue Ratio Atara Bio ATRA|IFRX - Market Cap to Revenue|XFOR: Market Cap to Revenue|ACET - P/S Multiple|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio INMB|BRNS (Barinthus Bio) - P/S Multiple|Price to Sales Kezar Life Sciences Inc KZR|P/S Multiple SABS|Price-to-Revenue Ratio AKTX (akaritx.com)|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GOVX - Price-to-Revenue Ratio|Price to Sales Edesa Biotech Corp|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CARM|Market Cap to Revenue XTLB|BOLT (Bolt Bio) - Market Cap to Sales Volume|P/S Multiple HCWB|APVO - Price to Sales|P/S Multiple AIM (AIM ImmunoTech Inc.)|ADTX - Market Cap to Revenue|GRI Bio - P/S Multiple|Market Capitalization-to-Revenue Ratio XRTX (XORTX Therapeutics Inc)|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Indaptus Therapeutics|scinai.com (SCNI) - Price-to-Revenue Coefficient|P/S Multiple CALI|AFMD - Price to Sales|P/S Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGMS - Price-to-Revenue Ratio|ITOS (iteostherapeutics.com) - Market Cap to Revenue Ratio|OCEA (Ocean Biomedical) - Market Cap to Revenue|TCBP: Market Cap to Sales Volume|Market Cap to Revenue THRD
